2-Thiazolidinone derivatives, pharmaceutical compositions containing them, process for preparing same, and use

Abstract: The present invention relates to novel 2-thiazolidi­ none derivatives of the general formula (I), wherein A stands for hydrogen, halogen or a C₁₋₄alkyl, C₁₋₄alkoxy or nitro group; and n is 0 or 1. The compounds according to the invention show a cytoprotective and gastric acid secretion-inhibiting effect and thus, may be used in the therapy of gastric and duodenal ulcers. The invention includes preparation methods for the above compounds with the general formula (I) and pharmaceutical compositions containing them.

Description: This invention relates to novel 2-thiazolidinone derivatives of the general formula (I), wherein A stands for hydrogen, halogen or a C₁₋₄alkyl, C₁₋₄alkoxy or nitro group; and n is 0 or 1 with the proviso that said derivative is not 3-(4-nitro-phenylmethyl)-2-thiazolidinone as well as the pharmaceutical compositions containing these compounds. The therapeutical importance of the novel compounds of general formula (I) is very high since the number of patients suffering from gastric and duodenal ulcers is continuously increasing both in the absolute as well as in the relative sense. Although a number of antiulcer drugs are available, a similar effect of only 2-(3,4-dimethoxyphenyl)-5-methyl-4-thiazolidinone (KM-1146) having a significantly different structure from the compounds of general formula (I) has been described within the substance class of the thiazolidines [Arzneim.-Forsch./Drug Res. 36 /II/8, 1236 (1986)]. Among the compounds of the general formula (I), 3-(4-nitrophenylmethyl)-2-thiazolidinone has only been reported in the literature, which is the product of the alkaline hydrolysis of 2-(4-nitrophenylmethylthio)-3-(4-nitrophenylmethyl)-2-thiazolinium bromide [3. Chem. Soc. 1971 , 103). This compound is disclaimed in the present invention. According to an other aspect of the invention, there are provided processes for the preparation of the new compounds of the general formula (I). a) According to one process for the preparation of 2-thiazolidinone derivatives of the general formula (I) a cysteamine derivative of the general formula (II), wherein A and n are as defined above, is reacted with a carbonic acid derivative of the general formula (III), wherein Y means halogen, amino, phenoxy or pyridyloxy group. b) A further preparation method for the compounds of the general formula (I) comprises subjecting a compound of the general formula (IV), wherein A and n are as defined above, to a thermal decomposition. c) Finally, the 2-thiazolidinone derivatives of the general formula (I) may be prepared by reacting a compound of the general formula (V), wherein A and n are as defined above and X stands for halogen, mesyloxy or tosyloxy group, with 2-thiazolidinone. The reaction according to process a) of the invention is carried out in the presence of a solvent. Depending on the reactivity of the reactants used, suitable solvents are C₁₋₅ alcohols, C₃₋₈ ketones, nitriles, aromatic or chlorinated hydrocarbons. It is usually suitable to accomplish the reaction at a temperature between 40 °C and 130 °C, optionally at the boiling point of the solvent used. The side products of the reaction depends on the nature of the leaving group. Hydrogen chloride or ammonia (when Y=NH₂) formed in the reaction partly evolve in a gaseous form from the reaction mixture whereas in other cases, phenol or hydroxypyridine formed in the condensation reaction have to be removed by alkaline extraction or distillation after evaporating the reaction mixture. From the reaction mixture thus pretreated, the product may be isolated by distillation, column chromatography or crystallization. The compounds of the general formula (IV) used as starting substances in process b) of the invention are prepared by nitrosating the corresponding imino compound or its salt. The compound of the general formula (IV) thus prepared is isolated, dried and subjected without purification to a thermal decomposition by refluxing in a high-boiling solvent (e.g. in a C₃₋₆ alcohol, C₆₋₁₀ aromatic hydrocarbon). After evaporation of the solvent, the residue is rubbed with a suitable solvent and the product is separated by filtration. The reaction according to process c) of the invention is carried out in the presence of a solvent. C₃₋₈ ketones or aqueous ketones, dimethylformamide, dimethylsulfoxide, preferably methyl isobutyl ketone may be used in the presence of an acid binding agent, preferably by using an alkaline metal carbonate or hydrogen carbonate for this purpose. After filtering off the inorganic precipitate and removing the solvent, the product is purified by distillation, crystallisation or column chromatography. The preparation of 2-thiazolidinone used as starting substance is known from the literature [3. Am. Chem. Soc. 73 , 5349 (1956); J. Chem. Soc. 1952 , 3094]. The cysteamine derivatives of the general formula (II) employed as starting compounds may be prepared by the complex metal hydride reduction of 2-arylthiazoline derivatives which in turn are obtained by reacting cysteamine with the appropriate oxo compounds [J. Org. Chem. 27 , 4712 (1963). The 2-aminothiazolidine derivatives of the general formula (IV) can be prepared by alkylation of the corresponding 2-amino-2-thiazoline derivatives [see e.g.: Zhurnal Obsch. Chim. 1962 , 3215). Based on the pharmacological investigations, 3-phenylmethyl-2-thiazolidinone (code name: RGH-6148) is an outstanding member of the compounds of general formula (I). Pharmacology 1) RGH-6148 has antisecretory effect in pylorus ligated (Shay-rat) rats. [Gastroenterology 5 , 43 (1945)] ED₅₀: 2.6 mg/kg p.o. and 3.7 mg/kg i.p.. This compound does not inhibit the stimulated (by histamine, charbachole, pentagastrine) acid secretion in perfused rat stomach. 2) Pretreatment with RGH-6148 shows cytoprotective (gastroprotective) effect against acidified-ethanol induced gastric damage: ED₅₀ = 6 mg/kg p.o. [Gastroenterology 77 , (1979)] 3) RGH-6148 prevents the gastric ulcer produced by a) indomethacin: ED₅₀ = 1.0 mg/kg p.o. b) aspirin: ED₅₀ = 1.3 mg/kg p.o. c) aspirin+stress ED₅₀ = 22.0 mg/kg p.o. 4) RGH-6148 accelerates the healing of chronic gastric ulcer in rats produced by acetic-acid at 3 mg/kg/daily with 38 %. 5) RGH-6148 inhibits the indomethacin-induced intestinal ulcer. 6) Acut LD₅₀ of RGH-6148 700 mg/kg p.o. in rat. Implications Together with some of literature findings, our present results suggest a working hypothesis for the pathomechanism of gastric ulcer and for the mechanism of action of RGH-6148. These hypotheses emphasized the role of mucosal mast cell. The fact that RGH-6148 does not inhibit the stimulated acid secretion suggests that the place of action might be as well on the level of mucosal mast cells, and not on the parietal cells one. RGH-6148 represents a new class of antiulcer drugs, which can be called as a mucosal mast cell protector (MMCP). 3-(2-Nitrophenylmethyl)-2-thiazolidinone, when orally administered in a dose of 10 mg/kg, resulted in 100% inhibition in the cytoprotective test (Robert test) in comparison to the control; and, when orally administered in a dose of 25 mg/kg, it induced 60% inhibition in the acid secretion-inhibiting test (Shay test) in comparison to the control. When tested by using the same method, 3-(4-chlorophenylmethyl)-2-thiazolidinone showed an inhibition of 30% and 60%, respectively. The invention is illustrated in detail by the following non-limiting Examples. Example 1 Preparation of 3-phenylmethyl-2-thiazolidinone a) A solution containing 33.6 g (0.2 mol) of N-phenylmethylcysteamine and 42.8 g (0.2 mol) of diphenyl carbonate in 200 ml of ethanol is refluxed under nitrogen for 24 hours, then ethanol is evaporated under reduced pressure. The residue is taken up in ethyl acetate, washed with 2N sodium hydroxide solution until it becomes free of phenol, then washed with water, dried and evaporated. The residue is distilled under reduced pressure to give 21.8 g (56.4%) of the title compound, b.p.: 140 o C/1.5 Hgmm, which solidifies under petroleum ether, m.p.: 50-51 o C. Analysis : calculated for C₁₀H₁₁NOS (molecular weight 193.26): C 62.15; H 5.73; N 7,25; S 16.59%; found C 62.23; H 5.98; N 7,17; S 16.45. IR (KBr): 1660 cm⁻¹ (C=0) 1445 cm⁻¹ (N-CH₂) 1230 cm⁻¹ (S-CH₂) ¹H-NMR (CDCl₃): 3.0-3.7 ppm (m, 4H,2CH₂) 4.5 ppm (s, 2H, CH₂) 7.3 ppm (s, 5H, ArH) b) After saturating 30 ml of toluene with phosgene at 10 o C, a solution of 10.02 g (0.06 mol) of N-phenylmethylcysteamine in 15 ml of toluene is added dropwise. A white, thick precipitate appears. The mixture is slowly heated to the boiling point and refluxed until a clear solution is obtained. The hot solution is bubbled through with nitrogen until it becomes free from phosgene and then evaporated under reduced pressure. The residue is refluxed in 40 ml of ethanol for 2 hours, then ethanol is evaporated under reduced pressure and the residue is distilled under reduced pressure. The distillate solidifies under petroleum ether. Thus, 6.65 g (57.3%) of the title compound are obtained, m.p.: 50-51 o C. c) To a solution of 2.73 g (0.01 mol) of 2-imino-3-phenylmethylthiazolidine hydrobromide in 10 ml of water 1.36 g of anhydrous sodium acetate and 0.62 ml of glacial acetic acid are added, then 0.75 g of sodium nitrite dissolved in 3 ml of water is dropped to the above mixture at 5 o C under stirring, then the mixture is stirred at 5 o C( for additional 3 hours. After standing in a refrigerator overnight, the solution is stirred at room temperature for 3 hours. After rubbing, a precipitate appears which is filtered off, washed with water, dried and then refluxed with five volumes of n-butanol for 2 hours. After evaporating the solvent, the residue is thoroughly rubbed with diisopropyl ether and the product is filtered off. Thus, 0,81 g (42.3 %) of the title product is obtained, m.p.: 49-50 o C. d) A mixture containing 3.09 g (0.03 mol) of 2-thiazolidine, 11.2 g of potassium carbonate, 1.8 g of potassium hydrogen carbonate, 0.5 ml of water, 30 ml of methyl isobutyl ketone and 3.0 ml (0.033 mol) of benzyl bromide is refluxed for 7 hours. After cooling down, the reaction mixture is washed twice with 30 ml of water each, the organic phase is dried and evaporated. The yellow oily product (which solidifies on standing) may be purified by column chromatography (by using Kieselgel 60 of a size of 0.063 to 0.037 mm (230-400 mesh) as sorbent and chloroform as eluent) to give 3.2 g (55.2%) of the title compound, m.p.: 50-51 o C. Example 2 Preparation of 3-(4-methoxyphenylmethyl)-2-thiazolidinone A solution containing 4.53 g (0.025 mol) of N-(4-methoxyphenylmethyl)-cysteamine and 5.35 g (0.025 mol) of diphenyl carbonate in 25 ml of ethanol is refluxed under nitrogen for 24 hours, then evaporated. The residue is taken up in ethyl acetate, washed with 2N sodium hydroxide solution until it becomes free from phenol, then washed with water, dried and evaporated. The residue becomes solid under ether. Thus, 1.82 g (32.6%) of the title compound are obtained, m.p.: 84-86 o C. Analysis : calculated for C₁₁H₁₃NO₂S (molecular weight 223.29): C 59.17; H 5.87; N 6.27; S 14.36%; found C 59.35; H 5.91; N 6.03; S 14.23. IR (KBr): 1640 cm⁻¹ (C=0) 2850 cm⁻¹ (O-CH₃) 1247 cm⁻¹ (Ar-O-C) ¹H-NMR (COCl₃): 3.3 ppm (m, 4H, 2CH₂) 3.8 ppm (s, 3H, CH₃) 4.4 ppm (s, 2H, CH₂) 7.0 ppm (q, 4H, ArH). Example 3 Preparation of 3-(2-chlorophenylmethyl)-2-thiazolidinone The procedure of Example 2 is followed, 5.05 g (0.025 mol) of N-(2-chlorophenylmethyl)cysteamine are reacted with 5.35 g (0.025 mol) of diphenyl carbonate and then worked up. The product is purified by column chromatography (by using Kieselgel 60 of a size of 0.063 to 0.037 mm (230-400) mesh as sorbent and chloroform as eluent) to obtain 2.5 g (43.9%) of the title compound, n 30 / D = 1.600. Analysis: calculated for C₁₀H₁₀ClNOS (molecular weight 227.71): C 52.75; H 4.43; N 6.15; S 14.07%; found C 52.98; H 4.25; N 6.28; S 14.22 IR (KBr): 1670 cm⁻¹ (C=0) 1055 cm⁻¹ (Ar-Cl) ¹H-NMR (COCl₃): 3.3 ppm (m, 2H, CH₂) 3.6 ppm (m, 2H, CH₂) 4.7 ppm (s, 2H, CH₂) 7.4 ppm (s, 5H, ArH). Example 4 Preparation of 3-(4-methylphenylmethyl)-2-thiazolidinone The procedure of Example 2 is followed, 4.0 g (0.022 mol) of N-(4-methylphenylmethyl)cysteamine are reacted with 4.71 g (0.022 mol) of diphenyl carbonate then the reaction mixture is worked up to give 1.36 g (29.8%) of the title compound, m.p.: 49-50 o C. Analysis : calculated for C₁₁H₁₃NOS (molecular weight 207.29): C 63.73; H 6.32; N 6.76; S 15.47%; found C 63.78; H 6.39; N 6.67; S 15.44. IR (KBr): 1660 cm⁻¹ (C=0) ¹H-NMR (CDCl₃): 2.2 ppm (s, 3H, CH₃) 2.9-3.6 ppm (m, 4H, 2CH₂) 4.3 ppm (s, 2H, CH₂) 7.0 ppm (s, 5H, ArH). Example 5 Preparation of 3-(2-nitrophenylmethyl)-2-thiazolidinone A mixture containing 3.09 g (0.03 mol) of 2-thiazolidinone, 11.2 g of potassium carbonate, 1.8 g of potassium hydrogen carbonate, 0.5 ml of water, 30 ml of methyl isobutyl ketone and 6.5 g (0.03 mol) of 2-nitrobenzyl bromide is refluxed for 6 hours, then cooled down and thoroughly mixed with 50 ml of water. The mixture is filtered and the clear filtrate is separated. The organic phase is washed with 10 ml of water, dried and evaporated. The oily residue is recrystallized from ethanol to give 2.65 g (37.0%) of the title compound, m.p.: 92-93 o C. Analysis : calculated for C₁₀H₁₀N₂O₃S (molecular weight 238.26): C 50.41; H 4.23; N 11.76; S 13.45%; found C 50.63; H 4.10; N 11.84; S 13.63. IR (KBr): 1670 cm⁻¹ (C=0) 1525, 1345 cm⁻¹ (NO₂) ¹H-NMR (CDCl₃): 3.1-3.8 ppm (m, 4H, 2CH₂) 4.9 ppm (s, 2H,CH₂) 7.2-8.3 ppm (m, 4H, ArH). Example 6 Preparation of 3-(4-chlorophenylmethyl)-2-thiazolidinone The process of Example 5 is followed, except that 5.0 g (0.03 mol) of 4-chlorobenzyl chloride are used instead of 2-nitrobenzyl bromide. Thus, 3.95 g (56%) of the title compound are obtained, m.p.: 68-69 o C. Analysis : calculated for C₁₀H₁₀ClNOS (molecular weight 227.71): C 52.75; H 4.43; N 6.15; S 14.07%; found C 52.83; H 4.67; N 6.12; S 14.24. IR (KBr): 1670 cm⁻¹ (C=0) 1095 cm⁻¹ (Ar-Cl) ¹H-NMR (CDCl₃): 3.3 ppm (q, 2H, CH₂) 3.5 ppm (q, 2H, CH₂) 4.5 ppm (s, 2H, CH₂) 7.3 ppm (s, 4H, ArH). Example 7 Preparation of 3-cinnamyl-2-thiazolidinone The process of Example 5 is followed, except that 4.58 g (0.03 mol) of cinnamyl chloride are used instead of 2-nitrobenzyl bromide. After purifying by chromatography (by using Kieselgel 60 of a size of 0.063 to 0.037 mm (230-400) mesh as sorbent and an 8:2 mixture of ethyl acetate and petroleum ether as eluent) and recrystallisation from diisopropyl ether, 3.92 g (59.6%) of the title product are obtained, m.p.: 50-52 o C. Analysis : calculated for C₁₂H₁₃NOS (molecular weight 219.30); C 65.72; H 5.97; N 6.39; S 14,62%; C 65,93; H 6.06; N 6.26; S 14.51. IR (KBr): 1670 cm⁻¹ (C=0) 980 cm⁻¹ (C=C) ¹H-NMR (CDCl₃): 3.2 ppm (m, 2H, CH₂) 3.6 ppm (m, 2H, CH₂) 4.0 ppm (d, 2H, CH₂) 5.9-6.6 ppm (m, 2H, 2CH) 7.3 ppm (s, 5H, ArH). Example 8 Pharmaceutical composition Preparation of tablets containing 50 mg of active ingredient each For the preparation of 1000 tablets, the following components are used: 3-Phenylmethyl-2-thiazolidinone 50 g Lactose 200 g Starch 32 g Magnesium stearate 3 g The active ingredient and the auxiliary materials are mixed in a mixer equipment and then compressed to tablets in a tabletting machine.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, NL, SE 2-Thiazolidinone derivatives of the general formula (I), wherein A stands for hydrogen, halogen or a C₁₋₄alkyl, C₁₋₄alkoxy or nitro group; and n is 0 or 1 with the proviso that said derivative is not 3-(4-nitro-phenylmethyl)-2-thiazolidinone. 3-Phenylmethyl-2-thiazolidinone. A process for the preparation of 2-thiazolidinone derivatives of the general formula (I) as set forth in claim 1 which comprises a) reacting a cysteamine derivative of the general formula (II), wherein A and n are as defined above, with a carbonic acid derivative of the general formula (III), wherein Y means halogen, amino, phenoxy or pyridyloxy group. A process for the preparation of 2-thiazolidinone derivatives of the general formula (I) as set forth in claim 1, which comprises subjecting a compound of the general formula (IV), wherein A and n are as defined above, to a thermal decomposition. A process for the preparation of 2-thiazolidinone derivatives of the general formula (I) as set forth in claim 1, which comprises reacting a compound of the general formula (V), wherein A and n are as defined above and X stands for halogen, mesyloxy or tosyloxy group, with 2-thiazolidinone. A process as claimed in claim 3, which comprises using diphenylcarbonate as compound of the general formula (III). A process as claimed in claim 3, which comprises using phosgene as a compound of the general formula (III) dissolved in an apolar solvent. A process as claimed in claim 4, which comprises carrying out the thermal decomposition of the compound of general formula (IV) in an organic solvent, preferably in butanol, at a temperature between 110 o C and 140 o C, preferably at 117 o C, at the boiling point of butanol. A process as claimed in claim 5, which comprises reacting a compound of the general formula (V) with 2-thiazolidinone in an organic solvent, preferably in a ketone-type solvent above 100 o C in the presence of an acid binding agent and water. A process as claimed in claim 8, which comprises using an alkaline metal carbonate and/or alkaline metal hydrogen carbonate as acid binding agent and 3 to 5% of water. A pharmaceutical composition, which comprises as active ingredient a 2-thiazolidinone derivative of the general formula (I), wherein A stands for hydrogen, halogen or a C₁₋₄alkyl, C₁₋₄alkoxy or nitro group; and n is 0 or 1 with the proviso that said derivative is not 3-(4-nitro-phenylmethyl)-2-thiazolidinone in admixture with carriers and/or additives commonly used in the pharmaceutical industry. A process for the preparation of a pharmaceutical composition, which comprises mixing as active ingredient a 2-thiazolidinone derivative of the general formula (I), wherein A and n are as defined in claim 1, prepared by using a process according to any of the claims 3 to 5 with carriers and/or additives commonly used in the pharmaceutical industry and transforming them to a pharmaceutical composition. Use of a 2-thiazolidinone derivative of the general formula (I) as set forth in claim 1 for making a medicament for the therapy of gastric and duodenal ulcers. Claims for the following Contracting States : ES, GR A process for the preparation of 2-thiazolidinone derivatives of the general formula (I), wherein A stands for hydrogen, halogen or a C₁₋₄alkyl, C₁₋₄alkoxy or nitro group; and n is 0 or 1, with the proviso that said derivative is not 3-(4-nitro-phenylmethyl)-2-thiazolidinone, which comprises reacting a cysteamine derivative of the general formula (II) wherein A and n are as defined above, with a carbonic acid derivative of the general formula (III), wherein Y means halogen, amino, phenoxy or pyridyloxy group. A process for the preparation of 2-thiazolidinone derivatives of the general formula (I) as set forth in claim 1, which comprises subjecting a compound of the general formula (IV), wherein A and n are as defined above, to a thermal decomposition. A process for the preparation of 2-thiazolidinone derivatives of the general formula (I) as set forth in claim 1, which comprises reacting a compound of the general formula (V), wherein A and n are as defined above and X stands for halogen, mesyloxy or tosyloxy group, with 2-thiazolidinone. A process as claimed in claim 1, which comprises using diphenylcarbonate as compound of the general formula (III). A process as claimed in claim 1, which comprises using phosgene as a compound of the general formula (III) dissolved in an apolar solvent. A process as claimed in claim 2, which comprises carrying out the thermal decomposition of the compound of general formula (IV) in an organic solvent, preferably in butanol, at a temperature between 110 o C and 140 o C, preferably at 117 o C, at the boiling point of butanol. A process as claimed in claim 3, which comprises reacting a compound of the general formula (V) with 2-thiazolidinone in an organic solvent, preferably in a ketone-type solvent above 100 o C in the presence of an acid binding agent and water. A process as claimed in claim 6, which comprises using an alkaline metal carbonate and/or alkaline metal hydrogen carbonate as acid binding agent and 3 to 5% of water. A process as claimed in one or more of the preceding claims for the preparation of 3-phenylmethyl-2-thiazolidinone. Use of a 2-thiazolidinone derivative of the general formula (I) as prepared in one or more of the preceding claims 1-8 for making a medicament for the therapy of gastric and duodenal ulcers. A process for the preparation of a pharmaceutical composition which comprises mixing as active ingredient a 2-thiazolidone derivative of the general formula (I), wherein A and n are as defined in claim 1, prepared by using a process according to any of the preceding claims 1-8, with carriers and/or additives commonly used in the pharmaceutical industry and transforming them to a pharmaceutical composition.

Inventors: DOMANY GYOERGY DR DIPL-CHEM, EZER ELEMER, HAJOS GYOERGY DR, HARSANYI KALMAN DR DIPL-CHEM, HEGEDUES BELA DR DIPL-CHEM, KAPOLNASNE PAP MARTA, LAMPERT AGNES, MATUZ JUDIT DR, SAGHY KATALIN DR, SZABADKAI ISTVAN, SZEKELY KRISZTINA, SZPORNY LASZLO DR, DOMANY, GYOERGY, DR. DIPL.-CHEM., EZER, ELEMER, HAJOS, GYOERGY, DR., HARSANYI, KALMAN, DR. DIPL.-CHEM., HEGEDUES, BELA, DR. DIPL.-CHEM., KAPOLNASNE PAP, MARTA, LAMPERT, AGNES, MATUZ, JUDIT, DR., SAGHY, KATALIN, DR., SZABADKAI, ISTVAN, SZEKELY, KRISZTINA, SZPORNY, LASZLO, DR., Domány, György, Dr. Dipl.-Chem., Ezer, Elemér, Hajós, György, Dr., Harsányi, Kálmán, Dr. Dipl.-Chem., Hegedüs, Béla, Dr. Dipl.-Chem., Kápolnásné Pap, Márta, Sághy, Katalin, Dr., Szabadkai, István, Székely, Krisztina, Szporny, László, Dr.
Applicants: RICHTER GEDEON VEGYESZET, RICHTER GEDEON VEGYESZETI GYAR R.T.
Application year: 1988
Main classification: C07D277
IPC codes: C07D275, A61K31, A61P1, C07D277